China Medical System Holdings Limited (0867.HK) HKSE

10.73

-0.32(-2.90%)

Updated at June 03 11:59AM

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
Kong Lam	Founder, Chairman, Chief Executive Officer & President	6.79M	1965
Yanling Chen	Chief Financial Officer, Vice President & Executive Director	5.36M	1970
Liu Yue	Director of Investor Relations	0	N/A
James Patrick Stearns	Chief Investment Officer of Europe & America	0	1979
Huaizheng Peng	Chief Business Officer	0	1962
Sanyan Wu	Director of Legal Department & Company Secretary	0	1983
Fei Jiang	Chief Investment Officer of Greater China	0	1977
Lieyi Ma	General Manager of the Operations & Management Center of the Group	0	1970

Name

Title

Pay

Year Born

Kong Lam

Founder, Chairman, Chief Executive Officer & President

6.79M

1965

Yanling Chen

Chief Financial Officer, Vice President & Executive Director

5.36M

1970

Liu Yue

Director of Investor Relations

N/A

James Patrick Stearns

Chief Investment Officer of Europe & America

1979

Huaizheng Peng

Chief Business Officer

1962

Sanyan Wu

Director of Legal Department & Company Secretary

1983

Fei Jiang

Chief Investment Officer of Greater China

1977

Lieyi Ma

General Manager of the Operations & Management Center of the Group

1970

Description

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.